The short answer
Rwanda FDA runs two doors into the same market. The full national assessment is processed within 12 months of receipt.[1] The abbreviated procedure — reliance on WHO prequalification, a stringent or WHO-Listed authority, or a positive EAC joint assessment recommendation — carries a published decision commitment of 90 calendar days.[2]
The fee schedule pushes the same way. Registration of an imported pharmaceutical product costs USD 300 from the EAC tier, USD 750 from the SRA/WLA tier and USD 2,000 from all other sources.[3] Getting into a recognised tier is worth roughly nine months and USD 1,700 per product.
Most exporters approach Rwanda the way they approach every other African market: assemble a CTD dossier, appoint an agent, file, and wait. That works. It is also the slowest and most expensive of the routes Rwanda FDA actually publishes, and a surprising number of Indian manufacturers file that way without ever checking whether they qualified for something faster.
This guide is built around the part almost nobody explains properly — the abbreviated procedure that Rwanda FDA domesticated from the East African Community joint assessment framework, who genuinely qualifies for it, and the uncomfortable reason most Indian generics do not qualify on the strength of their Indian approval alone.
The two doors: full assessment and abbreviated procedure
Rwanda FDA regulates human pharmaceutical products under two guidelines that entered into force on the same day, 29 February 2024. Guidelines for Registration of Human Pharmaceutical Products (DD/HMDR/GDL/001, Rev_1) governs the standard national route.[1] Guidelines on Abbreviated Procedures for Registration of Pharmaceutical Products (DD/HMDR/GDL/004, Rev. 1) governs everything else.[2]
The abbreviated guideline is not one pathway. It defines two, and the distinction decides how much work the Authority does on your dossier:
- Recognition (section 2.1) — routine acceptance of the reference authority’s decision, once Rwanda FDA has confirmed sameness of the product.
- Abridged assessment (section 2.2) — a limited independent assessment, used where sameness cannot be fully confirmed.
Both sit under the same published commitment: “The Authority shall process the application and communicate its decision on the product to the applicant within ninety (90) calendar days.”[2] The guideline draws no timeline distinction between recognition and abridged assessment.
The abbreviated guideline reserves the Authority’s discretion explicitly: it may “choose and confirm the appropriate assessment pathway and to shift from an abbreviated assessment to a full assessment pathway at any stage.”[2] Ninety days is a commitment attached to a pathway you can be moved out of. Plan the commercial timeline against the full route and treat the 90-day outcome as upside, not as the base case.
Rwanda’s three routes, side by side
| Dimension | Full national assessment | Recognition (abbreviated 2.1) | Abridged assessment (2.2) |
|---|---|---|---|
| Published decision window | Within 12 months of receipt [1] | 90 calendar days [2] | 90 calendar days [2] |
| What triggers eligibility | Open to any applicant meeting the guideline | Reference approval plus confirmed product sameness | Reference approval where sameness cannot be fully confirmed |
| Depth of review | Independent assessment of the full dossier | Routine acceptance of the reference decision | Limited independent assessment |
| Unredacted reference assessment reports | Not applicable | Required (quality, non-clinical, clinical, risk management) [2] | Required [2] |
| Dossier identity rule | Not applicable | Dossier submitted to Rwanda FDA must, at time of submission, be the same as that submitted to the reference authority; pending variations under assessment elsewhere must be excluded [2] | |
| Query rounds before rejection | Queries reissued a third time with unsatisfactory responses leads to rejection [1] | Not separately specified in the abbreviated guideline | |
| Marketing authorisation validity | Five (5) years [1] | ||
Scroll the table sideways on a phone.
Do you actually qualify? Check before you file
Eligibility for the abbreviated procedure is not a matter of persuasion. The guideline names the reference authorities it will rely on, and your product is either behind one of them or it is not.
Pathway eligibility check
Four questions. Answers are not stored or sent anywhere.
Answer all four questions
The result will name the Rwanda FDA pathway your product is eligible for and the evidence you would need to file with it.
Basis: DD/HMDR/GDL/004 Rev. 1 and DD/HMDR/GDL/001 Rev_1
The reference authorities Rwanda FDA will rely on
The abbreviated guideline lists the acceptable sources of a reference decision: stringent regulatory authorities (naming the EU Commission, US FDA and Japan’s PMDA), WHO-Listed Authorities, WHO transitional Listed Authorities in Category B, WHO-prequalified products, recommendations from EMA, the African Medicines Agency or the EAC joint assessment, and authorities at WHO maturity level 3 or above that hold a Memorandum of Understanding with Rwanda FDA.[2]
CDSCO is not a WHO-Listed Authority. WHO’s published WLA list, as at December 2025, contains 38 authorities plus the European Medicines Regulatory Network. India’s CDSCO does not appear on it.[4] An Indian marketing authorisation, on its own, does not open Rwanda’s abbreviated door.
That leaves three realistic routes for an Indian generic: WHO prequalification of the finished product, approval by an SRA or WLA such as a US ANDA or an EU authorisation, or a positive EAC joint assessment recommendation. For most Indian exporters without a US or EU filing, the EAC route is the accessible one.
The guideline also names the African Medicines Agency as a source of recommendations. AMA’s operational assessment capacity is still being built out; confirm its current status with Rwanda FDA in writing before building a filing plan around it rather than assuming the listing implies an available pathway today.
The EAC joint assessment route, and what it realistically delivers
Rwanda is a Partner State of the East African Community, and the EAC Medicines Regulatory Harmonisation programme runs a joint assessment procedure in which national authorities assess a dossier together and issue a joint recommendation. Rwanda FDA’s abbreviated guideline accepts that recommendation as a reference decision.[2]
The published evidence on how the procedure performs is worth knowing before you commit to it. A peer-reviewed evaluation of the EAC joint assessment procedure reported that, as at December 2021, 159 applications had been received, 144 assessed and 79 products recommended for registration through the joint procedure. Registration timelines for products using the process fell from roughly 24 months to 8–12 months over the 2012–2017 period, and the median time from a positive recommendation to national marketing authorisation sat between 30 and 90 days.[5]
The same study is candid about where it breaks. Companies reported that a positive EAC recommendation “does not directly result in individual country approvals”, and that national authorities “often request additional information after an EAC positive opinion, which further delays approval”.[5] A joint recommendation is a strong reference decision. It is not an East African marketing authorisation.
The EAC’s own harmonised procedural guidance sets national evaluation at 12 months for a standard application and 6 months for priority products, caps evaluation at four rounds, and gives applicants 180 calendar days to answer first-round questions and 120 calendar days for subsequent rounds.[6] Rwanda’s national 12-month figure is consistent with that framework.
Rwanda FDA was announced as having attained WHO Maturity Level 3 on 6 December 2024, for medicines and vaccines (non-producing), following a benchmarking exercise that ran from December 2022 to October 2024.[7] Africa CDC’s statement of 9 December 2024 placed Rwanda among eight African national regulatory authorities at ML3 — Egypt, South Africa, Tanzania, Nigeria, Ghana, Zimbabwe, Senegal and Rwanda — up from two in 2021.[8]
ML3 and WLA are different things. ML3 is a WHO benchmarking outcome; WLA is a separate WHO designation, and Rwanda FDA does not appear on the WLA list.[4] Do not conflate the two in a dossier cover letter.
What Rwanda FDA actually asks for: the CTD, module by module
Applications are submitted electronically through the Integrated Regulatory Information Management System (IRIMS) client portal at irims.rwandafda.gov.rw/portal. The dossier is filed in CTD format as PDF; the Quality Overall Summary and Quality Information Summary go in as MS Word documents, and all other documents must be selectable and searchable PDF.[1]
The scope matters: DD/HMDR/GDL/001 applies to human pharmaceutical products containing APIs of synthetic or semi-synthetic origin and fixed-dose combinations. Vaccines, biologicals and herbal medicines are excluded and are handled under separate guidelines.[1]
CTD requirements by module
Module 1 is where Rwanda-specific requirements live. Modules 2–5 follow the ICH CTD structure.
Module 1 — administrative and country-specific
The items DD/HMDR/GDL/001 requires in Module 1:[1]
- Cover letter, dated and signed by the applicant (Annex 1)
- Completed application form (Annex 2)
- Prescribing information / Summary of Product Characteristics
- Container labelling, mock-ups and specimens
- Patient information leaflet — required except for hospital-use-only medicines
- Signed expert declarations with educational and experience details (Annex 3)
- Quality Information Summary in the template format (Annex 4)
- Certificate of Suitability (CEP) or APIMF letter of access with written permission from the API manufacturer (Annexes 5–6)
- Rwanda FDA GMP certificate, or proof that a GMP inspection application has been filed with Rwanda FDA; WLA or ML3 certificates where available
- GCP/GLP accreditation evidence for clinical study sites
- Product registration status: EAC and SRA/WLA submissions with dates and outcomes
- Declaration of any prior rejection or withdrawal
- WHO prequalification evidence, where applicable
- Valid Certificate of Pharmaceutical Product and manufacturing authorisation
- Two commercial samples in final pack size with their certificates of analysis
Module 2 — summaries
Quality Overall Summary and, where applicable, non-clinical and clinical overviews and summaries. Rwanda FDA requires the QOS and the Quality Information Summary as editable MS Word files, not PDF — a small formatting requirement that is a common cause of a screening bounce.[1]
Use the current version of the QIS template from the Rwanda FDA guideline annexes rather than a template carried over from another EAC filing; the annex versions are tied to the 29 February 2024 revision.
Module 3 — quality
Full chemistry, manufacturing and controls data for drug substance and drug product, in ICH CTD structure. Two Rwanda-relevant points:
- Stability. The abbreviated guideline requires a long-term stability protocol and report conducted at Zone IVB conditions.[2] Data generated only at Zone II or Zone III conditions will not carry the filing.
- API source documentation. Either a CEP or an APIMF letter of access, with the API manufacturer’s written permission attached — a letter of access alone, without that permission, is incomplete.[1]
Modules 4 and 5 — non-clinical and clinical
For a generic, this is normally the bioequivalence study package plus the biowaiver justification where one applies. Clinical study sites must be supported by GCP or GLP accreditation evidence in Module 1.[1]
Where a reference authority has already assessed these modules, the abbreviated route replaces independent review with review of that authority’s own reports — which is why those reports must be supplied unredacted.[2]
Additional documents for the abbreviated procedure
On top of the standard dossier, DD/HMDR/GDL/004 requires:[2]
- Proof of registration or approval by the reference regulatory authority
- Unredacted assessment reports — quality, non-clinical, clinical and risk management
- Application form carrying technical information identical to the reference submission
- A product dossier matching the reference authority submission
- Executed and master batch manufacturing records
- Long-term stability protocol and report at Zone IVB conditions
- Current-version Quality Information Summary
- Rwanda-specific labelling
- Rwanda FDA GMP certificate or proof of inspection application
- For the WHO Collaborative Registration Procedure: the completed expression of interest form (Part A, Appendix 3)
The unredacted reports requirement is the one that stalls filings. Reference authorities do not hand these over on request, and originator or licensor consent has to be arranged early. Start that conversation before you plan a 90-day launch.
Fees and timelines: the Rwanda planner
Rwanda FDA’s current fee instrument is the Regulations governing tariff/fees for services rendered by Rwanda Food and Drugs Authority, ODDG/RES/TRG/001, Version 5 (Rev_4), in force from 31 December 2024.[3] It replaced an earlier schedule, and several figures moved materially — the import permit rate in particular. Agency blogs still quoting 2% of FoB for an import permit are working from the superseded document.
The registration fee is tiered:
| Fee line | Amount | Notes |
|---|---|---|
| Registration, pharmaceutical and other health products — EAC tier | USD 300 | Part I, item 1 |
| Registration — SRAs, WLAs tier | USD 750 | Part I, item 1 |
| Registration — other sources | USD 2,000 | Part I, item 1 |
| Renewal of marketing authorisation | 100% of initial fee | Part IV, item 11 — falls due at the five-year point |
| Major variation, pharmaceutical products | 50% of initial fee | Part III, item 10 |
| Annual retention and minor variations | Fee-waived | Annex II, waived services |
| GMP inspection, foreign site in Asia | USD 3,300 | Part VII, item 17 — covers up to five production lines at one site |
| GMP inspection, additional production line | USD 400 each | Annex III, note 6 |
| GMP inspection, foreign site in Africa | USD 2,000 | Part VII, item 17 |
| Import licence of regulated products | 0.2% of FoB | Part VIII, item 18 |
| Licence, private importer / distributor / wholesaler / retailer | FRW 100,000 | Part VI, item 14 |
Scroll the table sideways on a phone. All figures from ODDG/RES/TRG/001 Version 5 (Rev_4), in force 31 December 2024.
The tariff table labels the three registration tiers as products “to be imported from EAC”, “to be imported from SRAs, WLAs” and “to be imported from other sources”. Read literally, the tier follows the country the goods ship from. Read purposively — and you cannot import from an authority — it follows the authority that approved the product.
The difference is USD 1,250 per product for an Indian manufacturer holding a US or EU approval. Ask Rwanda FDA to confirm the applicable tier in writing before you budget, and keep the reply on file. We have flagged this rather than picking the reading that suits an exporter.
Rwanda registration and permit planner
Indicative first-year regulatory outlay. Fee lines only — excludes dossier preparation, sample shipping, local representative costs and testing.
Indicative only, not a quotation. Calculated from ODDG/RES/TRG/001 Version 5 (Rev_4) in force 31 December 2024, at 0.2% of FoB for the import licence and 100% of the initial fee at renewal. Confirm current tariffs with Rwanda FDA before committing budget.
Import permit, importer licence and the local technical representative
Registration and importation are two separate tracks, and exporters routinely discover the second one late. Three distinct things must exist before a consignment clears.
1. A local technical representative
A foreign applicant cannot hold a Rwandan marketing authorisation unaided. DD/HMDR/GDL/001 defines the local technical representative as “any registered company in Rwanda and licensed by Rwanda FDA to deal with regulated products that has received a mandate from the Applicant.”[1] Two conditions, both binding: the entity must already hold a Rwanda FDA licence, and it must hold your written mandate.
The licensing side sits under FDISM/FDIC/GDL/005 Rev 3. A human wholesale pharmacy must be run by a registered pharmacist and needs RDB registration, a lease or rent contract, a notarised degree with supply chain experience and a valid licence to practise, on premises of at least 90 square metres.[9] Verify these documents exist for any partner who offers to be your LTR — a mandate to an unlicensed entity is worth nothing at the counter.
2. Product registration, or an authorised exception
The import guideline is unambiguous: “All pharmaceutical products, medical devices/IVDS to be imported must be registered or granted special approval by the Authority.”[10] Special import authorisation exists for cases where no registered therapeutic equivalent is available in Rwanda — orphan medicines, emergency use, certain oncology treatments — and for clinical trial products.[10] It is an exception route, not a commercial entry strategy.
3. A per-consignment import licence
The import licence is granted for a single consignment, is valid for six months from date of issue and is renewable for three months, with applications processed in three working days.[10] Applications go through the Rwanda FDA online platform.[11]
Documents required with the application include a commercial invoice with the specified details, a packing list carrying batch numbers and expiry dates, a certificate of analysis, a certificate of compliance evidencing GMP, ISO, CE or GDP status, product labelling in an official language of Rwanda, and proof of the verification fee.[10][11]
A three-working-day import licence turnaround is fast by regional standards. It means your constraint is almost never the permit — it is the registration ahead of it and the batch documentation behind it. Build your CoA and packing list discipline first; the permit is the easy part.
Why Rwanda, in commercial terms
Rwanda is a small market that behaves like a strategic one. UN COMTRADE data records pharmaceutical product imports of US$98.25 million in 2022.[12] That will not carry a portfolio on its own. What it does carry is a regulator at ML3, inside the EAC, with a published 90-day reliance commitment and a fee schedule that rewards products already assessed elsewhere.
The sensible way to read Rwanda is as a reference registration in a harmonised bloc, not as a standalone revenue line — the same logic that makes Tanzania or Kenya a first EAC filing. If you are choosing a sequence across East Africa, our Kenya PPB registration guide, Tanzania TMDA process guide and Uganda NDA guide set out each authority’s own sequence and dossier expectations.
East Africa at a glance
| Country | Authority | EAC Partner State | WHO ML3 as at Dec 2024 [8] | Detailed guide |
|---|---|---|---|---|
| Rwanda | Rwanda FDA | Yes | Yes — medicines and vaccines, non-producing [7] | This page |
| Tanzania | TMDA | Yes | Yes | TMDA registration process |
| Kenya | Pharmacy and Poisons Board | Yes | Not on the Africa CDC list of eight | Kenya PPB registration guide |
| Uganda | National Drug Authority | Yes | Not on the Africa CDC list of eight | Uganda NDA registration guide |
| Nigeria | NAFDAC | No — ECOWAS | Yes | NAFDAC registration guide |
Scroll sideways on a phone. ML3 status reflects the eight authorities named in the Africa CDC statement of 9 December 2024; absence from that list is not a judgement on an authority’s capability.
Where Rwanda filings actually lose time
- Chasing 90 days without the unredacted reports. The abbreviated route stands or falls on reference assessment reports supplied in full. If the originator or licensor will not release them, you are on the 12-month route regardless of what your product is approved for.
- Sameness drift. A different API supplier, a reworked manufacturing process or a strength that exists only for the African market breaks the sameness test and moves you from recognition to abridged assessment — or out of the abbreviated procedure entirely.[2]
- Filing a dossier with a variation pending elsewhere. The guideline requires the technical part to be identical to the current approved version at the reference authority; a variation still under assessment must not be folded in.[2]
- Zone II stability data. Zone IVB long-term data is required. Re-running stability adds six to twelve months that no pathway choice recovers.[2]
- Incomplete screening submissions. Rwanda FDA notifies the applicant within 30 calendar days if a dossier is incomplete.[1] That is a fast bounce, but the clock restarts.
- Missing the API permission letter. A CEP or an APIMF letter of access with the API manufacturer’s written permission — the permission, not just the letter.[1]
- Missing the samples. Two commercial samples in final pack size with their certificates of analysis are a Module 1 requirement, not an afterthought at inspection.[1]
- Query timelines treated casually. If responses are not submitted within the specified timeline, the application is treated as withdrawn; a third round of unsatisfactory responses leads to rejection.[1]
Frequently asked questions
A new application under the full national route is processed within twelve months of receipt. Under the abbreviated procedure, Rwanda FDA commits to communicating its decision within ninety calendar days. Both figures are decision windows published in the Rwanda FDA guidelines of 29 February 2024, and both exclude the time you spend answering queries.
It is a reliance pathway set out in guideline DD/HMDR/GDL/004 Rev. 1. Where a product has been approved by a recognised reference authority, Rwanda FDA either recognises that decision outright after confirming product sameness, or performs a limited abridged assessment where sameness cannot be fully confirmed. Accepted reference sources include WHO prequalification, stringent regulatory authorities, WHO-Listed Authorities, and positive recommendations from the East African Community joint assessment procedure.
No. India’s CDSCO does not appear on WHO’s list of WHO-Listed Authorities as at December 2025, and it is not a stringent regulatory authority under the definition used in the Rwanda FDA guideline. An Indian manufacturer needs WHO prequalification of the finished product, an approval from an SRA or WLA such as the US FDA or the EU system, or a positive EAC joint assessment recommendation in order to enter the abbreviated pathway.
Under the tariff regulation in force from 31 December 2024, registration of an imported pharmaceutical product is USD 300 in the EAC tier, USD 750 in the stringent and WHO-Listed Authority tier, and USD 2,000 from other sources. A foreign GMP inspection of an Asian site is USD 3,300 covering up to five production lines, with USD 400 for each additional line. Renewal at the five-year point is charged at one hundred percent of the initial registration fee.
Yes. A foreign applicant must act through a local technical representative, defined in the Rwanda FDA registration guideline as a company registered in Rwanda, licensed by Rwanda FDA to deal with regulated products, and holding a mandate from the applicant. Both conditions matter: the entity must already hold the Rwanda FDA licence, and it must hold your written mandate.
An import licence is applied for through the Rwanda FDA online platform and is granted for a single consignment. It is valid for six months from the date of issue, renewable for three months, and applications are processed in three working days. The product must already be registered in Rwanda or hold a special approval, and the application must carry a commercial invoice, a packing list with batch numbers and expiry dates, a certificate of analysis, a certificate of compliance, labelling in an official language, and proof of the verification fee. The fee is 0.2 percent of FoB value.
No. A joint assessment recommendation is a reference decision that opens the abbreviated pathway; each Partner State still issues its own marketing authorisation. Published research on the EAC procedure found the median time from positive recommendation to national marketing authorisation ran between thirty and ninety days, and that national authorities frequently request additional information after a positive opinion.
Five years. Renewal is charged at one hundred percent of the initial registration fee. Annual retention and minor variations are listed among the fee-waived services in the current tariff regulation, while a major variation for a pharmaceutical product costs fifty percent of the initial fee.
The abbreviated procedures guideline requires a long-term stability protocol and report conducted at Zone IVB conditions. Products supported only by Zone II or Zone III long-term data will need stability re-run, which typically adds six to twelve months and cannot be recovered by choosing a faster assessment pathway.
Related on Puizer India
- Tanzania TMDA drug registration process The other EAC Partner State at WHO ML3 — the natural pairing for a two-country East African filing.
- Uganda NDA drug registration process Covers Uganda’s own reliance track and the manufacturer versus local technical representative split.
- Kenya PPB drug registration process Usually the first EAC filing by market size, and a common reference point for a regional sequence.
- NAFDAC drug registration process West Africa’s comparison case — a different bloc, a different set of rules.
- Pharmaceutical export to Africa: complete guide The hub guide covering documentation, WHO-GMP, MOQ and logistics across African markets.
- Third-party manufacturing for Africa: PCD, private label and contract manufacturing Explains which manufacturing model fits before you commit a dossier to one manufacturing site.
- Pharmaceutical import business in Nigeria The importer-side view: licensing, permits and the commercials of running an import operation.
Filing in Rwanda from an Indian manufacturing site
Puizer Pharmaceuticals (OPC) Pvt Ltd manufactures tablets, capsules, syrups, dry syrups and nutraceuticals from a WHO-GMP certified facility, and supplies the manufacturing-side documentation a Rwanda FDA dossier is built on — CTD Modules 2 and 3, site and GMP documentation, Certificate of Pharmaceutical Product support, batch records and stability data.
Tell us the molecules and the pack sizes you want in Rwanda and we will tell you honestly what your dossier is missing.
References
- Rwanda Food and Drugs Authority. Guidelines for Registration of Human Pharmaceutical Products. Doc. No. DD/HMDR/GDL/001, Rev_1. Kigali: Rwanda FDA; entry into force 29 February 2024. Available from: https://rwandafda.gov.rw/wp-content/uploads/2024/02/Guidelines%20for%20Registration%20of%20Pharmaceutical%20Products.pdf Accessed August 2026.
- Rwanda Food and Drugs Authority. Guidelines on Abbreviated Procedures for Registration of Pharmaceutical Products. Doc. No. DD/HMDR/GDL/004, Rev. 1. Kigali: Rwanda FDA; entry into force 29 February 2024. Available from: https://rwandafda.gov.rw/wp-content/uploads/2024/02/Guidelines_on_Abbreviated_Procedures_for_Pharmaceutical_Products_Registration.pdf Accessed August 2026.
- Rwanda Food and Drugs Authority. Regulations governing tariff/fees for services rendered by Rwanda Food and Drugs Authority. No. ODDG/RES/TRG/001, Version 5 (Rev_4). Kigali: Rwanda FDA; in force 31 December 2024. Available from: https://rwandafda.gov.rw/wp-content/uploads/2025/01/eRegulations-Governing-Fees_RFDA_31DECEMBER2024.pdf Accessed August 2026.
- World Health Organization. List of WHO Listed Authorities (WLAs). Geneva: WHO; December 2025. Available from: https://cdn.who.int/media/docs/default-source/medicines/regulatory-systems/wla/list_of_wla.pdf Accessed August 2026.
- Ngum N, Mashingia J, Ndomondo-Sigonda M, Walker S, Salek S. Evaluation of the effectiveness and efficiency of the East African Community joint assessment procedure by pharmaceutical companies: opportunities for improvement. Front Pharmacol. 2022;13:1031289. Available from: https://doi.org/10.3389/fphar.2022.1031289 Accessed August 2026.
- East African Community. Part X: Guidelines on Procedural Aspects for Applications for Marketing Authorization of Pharmaceutical Products. Arusha: EAC Secretariat. Available from: https://www.eac.int/medicines-regulatory-guidelines Accessed August 2026.
- Rwanda Food and Drugs Authority. Rwanda FDA Attains WHO Maturity Level 3. Kigali: Rwanda FDA; 6 December 2024. Available from: https://rwandafda.gov.rw/rwanda-fda-attains-who-maturity-level-3/ Accessed August 2026.
- Africa Centres for Disease Control and Prevention. Statement from Africa CDC on Rwanda and Senegal National Regulatory Authorities Achieving WHO Maturity Level 3. Addis Ababa: Africa CDC; 9 December 2024. Available from: https://africacdc.org/news-item/statement-from-africa-cdc-on-rwanda-and-senegal-national-regulatory-authorities-achieving-who-maturity-level-3/ Accessed August 2026.
- Rwanda Food and Drugs Authority. Guidelines on Licensing of Public and Private Manufacturers, Distributors, Wholesalers and Retailers of Medical Products. Doc. No. FDISM/FDIC/GDL/005, Rev. 3. Kigali: Rwanda FDA; effective 26 September 2022. Available from: https://rwandafda.gov.rw/wp-content/uploads/2022/11/Guidelines_on_licensing_of_public_and_private_manufacturer__distributors_wholesalers_and_retailers_of_medical_products.pdf Accessed August 2026.
- Rwanda Food and Drugs Authority. Guidelines for Importation and Exportation of Pharmaceutical Products and Medical Devices. Doc. No. FDSIM/FDIEC/GDL/001, Rev. 1. Kigali: Rwanda FDA; effective 30 November 2022. Available from: https://rwandafda.gov.rw/wp-content/uploads/2022/12/Guidelines-for-Importation-and-Exportation-of-Pharmaceutical-Products-and-Medical-Devices.pdf Accessed August 2026.
- Rwanda Food and Drugs Authority. Summary Requirements for Authorization to Import Regulated Products. Ref. No. ODDG/3922/FDA/2024. Kigali: Rwanda FDA; 6 September 2024. Available from: https://rwandafda.gov.rw/wp-content/uploads/2024/09/Summary-Requirements-for-authorization-to-import-regulated-products_Rwanda-FDA.pdf Accessed August 2026.
- United Nations COMTRADE database on international trade, via Trading Economics. Rwanda Imports of Pharmaceutical Products. Figure for 2022: US$98.25 million. Available from: https://tradingeconomics.com/rwanda/imports/pharmaceutical-products Accessed August 2026.
Technical and educational content, not regulatory, legal or investment advice. Rwandan guidelines, tariff regulations and EAC procedures are revised regularly, and the tariff instrument cited here replaced an earlier schedule in December 2024. Verify every figure, document number and timeline directly with Rwanda FDA and your local technical representative before committing filings, budgets or launch dates. Where this page identifies an ambiguity in the source text, it says so rather than resolving it in the exporter’s favour.
Last reviewed against source documents: August 2026.
